Status:
COMPLETED
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
Lead Sponsor:
Bo Feldt-Rasmussen
Conditions:
End-stage Renal Disease
Eligibility:
All Genders
18-90 years
Brief Summary
Patients with end-stage renal disease (ESRD) have a high prevalence of impaired glucose metabolism. The pathophysiological cause is uncertain, but disturbances in the secretion, elimination and effect...
Detailed Description
The effect of the incretin hormones on the endocrine pancreatic function in a uremic environment will be explored during fasting and hyperglycemic conditions in three randomised examination days. At ...
Eligibility Criteria
Inclusion
- Inclusion Criteria (End-stage renal disease):
- Chronic hemodialysis-dependent uremia in more than 3 months
- Inclusion Criteria (Healthy controls):
- Normal kidney function
- Exclusion Criteria:
- Fasting plasma glucose ≥ 6.1 mmol/l
- 2h plasma glucose ≥ 7.8 after ingestion of 75 grams of glucose
- Admittance to a hospital
- Anemia (Hb \< 6.0 mmol/l)
- Ongoing treatment with drugs interfering with glucose metabolism including steroids and calcineurin inhibitors
- Bowel resection or any other large abdominal surgery
Exclusion
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 28 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02237521
Start Date
September 1 2014
End Date
April 28 2016
Last Update
May 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Rigshospitalet
Copenhagen, Denmark, 2100